Marie-Josée and Henry R. Kravis Center for Molecular Oncology, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA.
Human Oncology and Pathogenesis Program, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA.
Cancer Cell. 2018 Nov 12;34(5):852-862.e4. doi: 10.1016/j.ccell.2018.10.003. Epub 2018 Nov 1.
Driver mutations in oncogenes encode proteins with gain-of-function properties that enhance fitness. Heterozygous mutations are thus viewed as sufficient for tumorigenesis. We describe widespread oncogenic mutant allele imbalance in 13,448 prospectively characterized cancers. Imbalance was selected for through modest dosage increases of gain-of-fitness mutations. Negative selection targeted haplo-essential effectors of the spliceosome. Loss of the normal allele comprised a distinct class of imbalance driven by competitive fitness, which correlated with enhanced response to targeted therapies. In many cancers, an antecedent oncogenic mutation drove evolutionarily dependent allele-specific imbalance. In other instances, oncogenic mutations co-opted independent copy-number changes via the evolutionary process of exaptation. Oncogenic allele imbalance is a pervasive evolutionary innovation that enhances fitness and modulates sensitivity to targeted therapy.
驱动基因突变编码具有获得性功能的蛋白质,从而增强适应性。因此,杂合突变被认为足以引起肿瘤发生。我们描述了在 13448 例前瞻性特征明确的癌症中广泛存在的致癌突变等位基因失衡。通过适度增加适应性获得性突变的剂量,选择了失衡。负选择针对剪接体的单倍体必需效应物。正常等位基因的丢失构成了一种由竞争适应性驱动的独特的失衡类型,这与对靶向治疗的增强反应相关。在许多癌症中,先前的致癌突变驱动了与进化相关的等位基因特异性失衡。在其他情况下,致癌突变通过进化过程的适应化过程共同采用了独立的拷贝数变化。致癌等位基因失衡是一种普遍的进化创新,可增强适应性并调节对靶向治疗的敏感性。